Clinical Trial

Enhancing Rehabilitation in Aging Study (ERAS)

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.
Trial Details
NCT Number NCT07704385
Lead Sponsor University of Florida
Conditions Adults
Enrollment 38 participants
Start Date 2026-10-01
Primary Completion 2031-05-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15